eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc. (Nasdaq: EFTR) is a clinical-stage biopharmaceutical company focused on oncology, specifically targeting the regulation of mRNA translation initiation as a therapeutic modality for cancer. The company became a publicly traded entity in 2021 through its merger with Locust Walk Acquisition Corp., a blank-check company affiliated with Locust Walk, a life sciences-focused advisory and investment firm. The 10-Q filed on August 12, 2021, bearing accession number 0001193125-21-244053, represents one of eFFECTOR's earliest quarterly disclosures as a post-merger public company. For full filing history, SPAC transaction data, and ongoing analytics on eFFECTOR Therapeutics, sign up for a SpacDesk account at spacdesk.com.